NeuraVia, Inc.

NeuraVia, Inc. is a dynamic and innovative company dedicated to revolutionizing neurological healthcare through advanced Artificial Intelligence solutions. Based in Wilmington, Delaware, with its primary address at 251 Little Falls Dr, Wilmington, Delaware 19808, US, NeuraVia, Inc. is focused on developing remote AI progression models specifically for Alzheimer’s disease. This pioneering approach enables earlier detection, more effective monitoring, and timely intervention, ultimately improving patient outcomes and addressing a critical unmet need in global healthcare.

NeuraVia, Inc. is committed to advancing its technology through rigorous clinical research and regulatory approval processes, currently progressing through Advarra REB in the U.S. and Canada. This dedication underscores the company's commitment to delivering safe, effective, and reliable AI-powered solutions. The company’s vision extends beyond developed markets, with preparations underway for strategic market entry in Nigeria and India, regions where affordable and scalable neurological care is urgently needed.

With a team of dedicated professionals, NeuraVia, Inc. is poised to become a leader in neurotechnology and digital health. The company is focused on delivering exceptional value to patients, healthcare providers, and the global community. NeuraVia, Inc. is dedicated to continual innovation and expanding the possibilities of AI in neurological healthcare. The management is eager to provide a customized and exclusive company showcase and product listing on our platform, further highlighting the transformative work of NeuraVia, Inc.